OP-1118

Overview

OP-1118 (Fidaxomicin metabolite OP-1118) is an orally active dual inhibitor of NF-κB and ERK1/2 , with low systemic plasma exposure, no accumulation, and primary excretion via feces. By inhibiting the phosphorylation of NF-κB and ERK1/2 and reducing the expression of pro-inflammatory cytokines, OP-1118 exerts significant anti-inflammatory, cytoprotective, anti-apoptotic and antibacterial activities. In Clostridium difficile infection models, OP-1118 effectively blocks toxin-mediated intestinal inflammation, cell rounding, histological damage and apoptosis , and its protective effect can be reversed by PMA ( HY-18739 ).

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Bacterial Infection | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Signaling Pathways > Bacterial | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > ERK | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-138135
• CAS No.: 1030825-28-5
• Molecular Formula: C48H68Cl2O17
• Molecular Weight: 987.95
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source